Intravenous immunoglobulin treatment and evaluation of autoinflammatory and immunodeficiency-associated recurrent parotitis cases in children

Year 2025, Volume: 42 Issue: 1, 58 - 62, 28.03.2025

Şefika İlknur Kökçü Karadağ , Ömer Salih Akar , Engin Altundağ , Alişan Yıldıran

Abstract

Abstract:
Recurrent juvenile parotitis is a rare inflammatory condition characterized by recurrent, non-obstructive, and non-suppurative inflammation of the parotid gland during childhood. Diagnosis of the disease is based on clinical symptoms and laboratory tests. Although cases of recurrent parotitis are rare, various diseases can contribute to its etiology. Case series in the literature have reported diagnoses of immunodeficiency and autoimmune diseases. This study presents five cases diagnosed with autoimmune disease and immunodeficiency, successfully treated with intravenous immunoglobulin.

Keywords

Recurrent Parotitis, Intravenous Immunoglobulin, Immunodeficiency

Ethical Statement

This study obtained approval from the local ethics committee of *****Mayıs University (Number 2024/261). Patients' informed consent was obtained. Our study was conducted in accordance with the Helsinki Declaration.

Supporting Institution

This study did not receive any funding.

References

• 1. Okuda S, Kamei S, Sasaki T. Immunoglobulin G Enhances Generation of Inducible T Regulatory Cells and Increases Their Regulatory Function. Biol Pharm Bull. 2018;41(12):1830-1836. doi:10.1248/bpb.b18-00548
• 2. Hidalgo-Santos AD, Gastón-Téllez R, Ferrer-Lorente B, Pina-Pérez R, Oltra-Benavent M. Immune disorders associated with juvenile recurrent chronic parotitis. An Pediatr (Engl Ed). 2021;95(4):260-266. doi:10.1016/j.anpede.2020.08.012
• 3. Leerdam CM, Martin HC, Isaacs D. Recurrent parotitis of childhood. J Paediatr Child Health. 2005;41(12):631-634. doi:10.1111/j.1440-1754.2005.00773.x
• 4. Ericson S, Zetterlund B, Ohman J. Recurrent parotitis and sialectasis in childhood. Clinical, radiologic, immunologic, bacteriologic, and histologic study. Ann Otol Rhinol Laryngol. 1991;100(7):527-535. doi:10.1177/000348949110000702
• 5. Yıldıran A. Autoinflammatory Diseases and Their Genetic Markers. Turkiye Klinikleri J Pediatr Sci 2016;12(4):16-28
• 6. Celiksoy MH, Ogur G, Yaman E, et al. Could familial Mediterranean fever gene mutations be related to PFAPA syndrome?. Pediatr Allergy Immunol. 2016;27(1):78-82. doi:10.1111/pai.12490
• 7. Akar HH, Patıroglu T, Duman L. A selective IgA deficiency in a boy who presented recurrent parotitis. Eur J Microbiol Immunol (Bp). 2014;4(2):144-146. doi:10.1556/EuJMI.4.2014.2.8
• 8. Wu S, Shi H, Cao N, Ye L, Yu C, Zheng L. The correlation of immunologic derangement and juvenile recurrent parotitis: an investigation of the laboratory immunological observation. Acta Otolaryngol. 2018;138(12):1112-1116. doi:10.1080/00016489.2018.15154989
• 9. Wood J, Toll EC, Hall F, Mahadevan M. Juvenile recurrent parotitis: Review and proposed management algorithm. Int J Pediatr Otorhinolaryngol. 2021 Mar;142:110617. doi: 10.1016/j.ijporl.2021.110617. Epub 2021 Jan 4. PMID: 33421670.
• 10. Maddur MS, Othy S, Hegde P, Vani J, Lacroix-Desmazes S, Bayry J, Kaveri SV. Immunomodulation by intravenous immunoglobulin: role of regulatory T cells. J Clin Immunol. 2010 May;30 Suppl 1:S4-8. doi: 10.1007/s10875-010-9394-5. PMID: 20405183.
• 11. Fonseca R, Gonçalves D, Aguiar F, Abelha-Aleixo J, Madureira P, Vieira R, et al. Intravenous Immunoglobulin (IVIG) is Effective and Safe in Severe or Refractory Rheumatic Diseases. Ann Rheum Dis. 2014 Jun;73(Suppl 2):1109–1110. doi:10.1136/annrheumdis-2014-eular.4592
• 12. Garcia-Geremias M, Carreño E, Epps SJ, Lee RW, Dick AD. Clinical outcomes of intravenous immunoglobulin therapy in refractory uveitis. Int Ophthalmol. 2015 Apr;35(2):281-5. doi: 10.1007/s10792-015-0051-0. Epub 2015 Feb 24. PMID: 25708281.
• 13. Wildman SHA, Al‐Obaidi M. P136 – Adverse reaction with intravenous immunoglobulin (IVIG) therapy and management of symptoms: A single centre experience. Rheumatology. 2020;59(Suppl_1). doi:10.1093/rheumatology/keaa111.131
• 14. Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev. 2007;6(4):257–259. doi:10.1016/j.autrev.2006.08.011